《生命科学》 2023, 35(12): 1689-1703

用于治疗阿尔茨海默病的三款抗β淀粉样蛋白抗体的专利布局分析

吴海燕 , 张　超 , 黄　放^*

复星安特金(成都)生物制药有限公司，成都 610219

摘　要：

淀粉样蛋白级联假说认为，β 淀粉样蛋白(Aβ) 的异常沉积在阿尔茨海默病(AD) 进展中具有核心作用，基于该假说，靶向Aβ 的抗体被推测可用于缓解AD 进展。然而，众多候选抗体在临床试验阶段折戟沉沙，目前到达Ⅲ期临床终点的仅有三款抗体，即Aducanumab、Lecanemab 和Donanemab，其中前两款抗体已在美国获批上市。针对该三款将在市场中展开激烈角逐的Aβ 抗体，现对其专利保护和布局情况进行深入分析，以供同行参考。

通讯作者：黄　放 , Email:huangfang@fosunpharma.com

Patent portfolio analysis of three anti-amyloid β antibodies for treating Alzheimer's disease

WU Hai-Yan , ZHANG Chao , HUANG Fang^*

Fosun Adgenvax (Chengdu) Biopharmaceutical Co., Ltd, Chengdu 610219, China

Abstract:

Based on the amyloid cascade hypothesis that abnormal deposition of β-amyloid (Aβ) plays a central role in the progression of Alzheimer's disease (AD), antibodies targeting Aβ are speculated to be useful in alleviating AD progression. However, multiple candidate antibodies have failed in the clinical trial stage. Currently, only three antibodies have reached the end point of phase Ⅲ clinical trials, namely Aducanumab, Lecanemab and Donanemab, in which the first two antibodies have been approved for marketing in the United States. For the three Aβ antibodies that will compete fiercely in the market, an in-depth analysis of their patent protection and layout is conducted in this article for reference by peers.

Communication Author：HUANG Fang , Email:huangfang@fosunpharma.com